Profile data is unavailable for this security.
About the company
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
- Revenue in USD (TTM)1.34m
- Net income in USD-72.21m
- Incorporated1998
- Employees25.00
- LocationNorthwest Biotherapeutics IncSUITE 800, 4800 MONTGOMERY LANEBETHESDA 20814United StatesUSA
- Phone+1 (240) 497-9024
- Fax+1 (302) 636-5454
- Websitehttps://nwbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Korro Bio Inc | 0.00 | -81.19m | 448.35m | 94.00 | -- | 2.56 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 448.69m | 224.00 | -- | 0.7439 | -- | 6,598.43 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -75.92m | 452.71m | 100.00 | -- | 1.25 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Aura Biosciences Inc | 0.00 | -78.65m | 456.79m | 88.00 | -- | 2.19 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -14.53m | 457.48m | 9.00 | -- | 1.79 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 459.13m | 29.00 | -- | 5.27 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 461.16m | 52.00 | -- | 7.95 | -- | 32.58 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Exscientia PLC (ADR) | 25.51m | -168.23m | 468.27m | 483.00 | -- | 1.59 | -- | 18.36 | -1.33 | -1.33 | 0.2018 | 3.41 | 0.0364 | -- | 34.98 | 52,807.47 | -24.02 | -- | -27.31 | -- | -34.40 | -- | -659.56 | -- | -- | -- | 0.0556 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Editas Medicine Inc | 69.41m | -166.13m | 470.40m | 265.00 | -- | 1.60 | -- | 6.78 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Ocugen Inc | 7.05m | -58.50m | 470.96m | 65.00 | -- | 15.56 | -- | 66.80 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| C4 Therapeutics Inc | 20.04m | -126.07m | 472.01m | 145.00 | -- | 1.83 | -- | 23.56 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 474.86m | 162.00 | -- | 1.39 | 312.82 | 3.99 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 475.63m | 25.00 | -- | -- | -- | 356.01 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Absci Corp | 5.35m | -109.19m | 495.31m | 155.00 | -- | 2.06 | -- | 92.63 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -40.59m | 501.08m | 40.00 | -- | 3.67 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 507.69m | 181.00 | -- | 1.19 | -- | 78.37 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Data as of Jul 22 2024. Currency figures normalised to Northwest Biotherapeutics Inc's reporting currency: US Dollar USD
1.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Link Fund Solutions Ltd.as of 30 Jun 2019 | 16.29m | 1.35% |
| Moloney Securities Asset Management LLCas of 31 Mar 2024 | 379.46k | 0.03% |
| Opus Capital Group LLCas of 31 Mar 2024 | 60.15k | 0.01% |
| Williams Jones Wealth Management LLCas of 31 Mar 2024 | 40.00k | 0.00% |
| MariPau Wealth Management LLCas of 31 Mar 2024 | 39.49k | 0.00% |
| Ethos Financial Group LLCas of 31 Mar 2024 | 23.70k | 0.00% |
| Lee, Danner & Bass, Inc.as of 31 Dec 2023 | 20.00k | 0.00% |
| Advisors Management Group, Inc.as of 31 Mar 2024 | 10.27k | 0.00% |
| Manulife Investment Management Ltd.as of 31 Mar 2024 | 3.46k | 0.00% |
| Coston, McIsaac & Partners, Inc.as of 31 Mar 2024 | 1.00k | 0.00% |
More ▼
Data from 31 Dec 2023 - 18 Jul 2024Source: FactSet Research Systems Inc.
